Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib versus S-1 maintenance after first-line chemotherapy for advanced gastric cancer
ChiCTR1800019382Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800019382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019382.